ArticleMedical mycology2026
Microsporum canis complex infections in the United Arab Emirates: Clinical, molecular, and antifungal susceptibility profiles.
Article in Medical mycology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Microsporum canis complex infections remain a major cause of pediatric dermatophytosis, yet molecular epidemiologic and antifungal susceptibility data from the Arabian Gulf are scarce, with no contemporary regional assessment since 1981-1988. We characterized the clinical, molecular, and antifungal susceptibility profiles of M. canis complex isolates in Abu Dhabi and assessed concordance between phenotypic and ITS-based identification. Fifty-two clinical dermatophyte isolates collected through passive surveillance at the UAEU Fungal Reference Laboratory (September 2024-December 2025) underwent phenotypic identification, ITS sequencing, and antifungal susceptibility testing (CLSI M38). Clinical data were available for 48 patients. ITS sequencing identified 47 isolates (90.4%) as M. canis and 5 (9.6%) as the M. audouinii clade, with phenotypic discordance in 9.6% of isolates (including one M. canis misidentified as Trichophyton rubrum). The cohort was predominantly pediatric (79.2% ≤12 years; 54.2% female). Tinea capitis predominated (60.4%), followed by tinea corporis (20.8%) and multifocal disease (16.7%). Cat exposure was reported in 50% and infected household contact in 27.1%. All isolates showed low minimum inhibitory concentrations (MICs ; terbinafine MIC₅₀/₉₀ 0.015/0.03; itraconazole ≤ 0.03/0.06; voriconazole ≤ 0.03/≤0.03; griseofulvin 0.125/0.25; fluconazole 4/8 µg/ml). Despite this, 81.2% (26/32) of patients with follow-up experienced treatment failure or recurrence, with no clear MIC-outcome association. This first molecular and antifungal characterization of M. canis complex infections in the UAE over three decades showed that ITS sequencing corrected phenotypic identification in nearly 10% of cases. High recurrence despite low MICs suggests limited predictive value of in vitro susceptibility, supporting species-directed management, molecular confirmation, species-directed management, and One Health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.